Xuebao Zheng
Guangdong Medical College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Xuebao Zheng.
Molecular Biology Reports | 2014
Hua Ye; Qiong Wu; Yuzhen Zhu; Cancan Guo; Xuebao Zheng
Ginsenoside Rh2 (GRh2) has been reported to have therapeutic effects on various diseases. However, whether it may also affect the recovery from ulcerative colitis remains unknown. Here we induced colitis in mice by dextran sulfate sodium (DSS) administration, and then treated the mice with GRh2. We found that GRh2-treated mice showed significant alleviation of the DSS-induced colitis. Moreover, significant increase in the activity of TGFβ signaling was detected in the GRh2-treated colon that had received DSS. To investigate whether there is a causative link among GRh2 treatment, TGFβ signaling augment and the cure of colitis, we gave the DSS-treated mice a combination of GRh2 and a specific TGFβ receptor I inhibitor, SB431542. SB431542 significantly decreased the activation of TGFβ signaling in the colon from the GRh2-administrated mice, and consequently attenuated the therapeutic effect of GRh2. Our data thus demonstrate that GRh2 may alleviate DSS-induced colitis via augmenting TGFβ signaling.
Diagnostic Pathology | 2015
Hua Ye; Liping Pang; Qiong Wu; Yuzhen Zhu; Cancan Guo; Ying Deng; Xuebao Zheng
BackgroundColorectal cancer (CRC) is one of the most common cancer and the leading causes of cancer mortality worldwide. The critical role of hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF) are important in the cancer development.MethodsThe purpose of this study was to investigate the association of miR-199a expression in CRC and non-tumor tissues as well as assessed the effect of miR-199a on biological behaviors including cell proliferation, apoptosis, migration and invasion of CRC cells. The expression of miR-199a was distinctly decreased in colorectal cancer tissues compared with non-neoplastic colorectal tissues.ResultsIn this study, we found that miR-199a down-regulation was associated with the CRC and metastasis incidence. Advanced study showed that miR-199a up-regulation would lead to decreased CRC proliferation, migration and invasion. However, no significant association of miR-199a treatment and apoptosis rate and cell-cycle were detected in this study. The detection for the mechanisms of miR-199a on the development of CRC showed that the anticarcinogenic effect of miR-199a might be produced through HIF-1α/VEGF pathway.ConclusionIt was found that miR-199a would reduce the proliferation, migration and invasion. However, overexpression of miR-199a on the apoptosis rate and cell cycles showed no significant results. The potential functionary mechanism of miR-199a might through HIF-1α/VEGF pathway.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9806714131513041.
Molecular Medicine Reports | 2016
Hua Ye; Qiong Wu; Meng Guo; Kefeng Wu; Yingnian Lv; Feng-Yan Yu; Yi Liu; Xiaosheng Gao; Yuzhen Zhu; Liao Cui; Nianci Liang; Tu Yun; Li Li; Xuebao Zheng
The aim of the present study was to investigate the mechanism underlying the antitumor effects of ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F) in colorectal cancer (CRC). 5F was isolated and used to treat C26 murine colon carcinoma cells, a xenograft tumor mouse model (induced by C26 cells) and a CRC mouse model [induced by 1,2-dimethylhydrazine (DMH)/dextran sodium sulfate (DSS)]. C26 cell growth was inhibited by 5F in a dose- and time-dependent manner in vitro. In addition, 5F induced cell apoptosis and cell cycle arrest in the G2 phase, increased the activity of caspase-3 and caspase-9, but did not affect the activity of cascase‑8, suggesting that 5F induced apoptosis via activation of the mitochondrial signaling pathway rather than the death‑receptor signaling pathway. Furthermore, treatment of C26 cells with 5F resulted in upregulation of cyclin‑dependent kinase inhibitor 1A (p21, Cip1), Bcl‑2‑associated X protein, nuclear factor of κ light polypeptide gene enhancer in B‑cells inhibitor, α and downregulation of B‑cell lymphoma 2, nuclear factor κ‑light‑chain enhancer of activated B cells and survivin. In vivo animal models demonstrated that 5F treatment protected mice from carcinogenesis induced by DMH/DSS and markedly decreased the xenograft tumor weight with minimal side effects. Therefore, 5F may have potential as an anti-CRC therapeutic agent for use in the clinical setting.
World Journal of Gastroenterology | 2015
Jin-Shan Feng; Ying Ye; Cancan Guo; Bo-Tao Luo; Xuebao Zheng
Ulcerative colitis in addition to inflammatory polyposis is common. The benign sequel of ulcerative colitis can sometimes mimic colorectal carcinoma. This report describes a rare case of inflammatory polyposis with hundreds of inflammatory polyps in ulcerative colitis which was not easy to distinguish from other polyposis syndromes. A 16-year-old Chinese male suffering from ulcerative colitis for 6 mo underwent colonoscopy, and hundreds of polyps were observed in the sigmoid, causing colonic stenosis. The polyps were restricted to the sigmoid. Although rectal inflammation was detected, no polyps were found in the rectum. A diagnosis of inflammatory polyposis and ulcerative colitis was made. The patient underwent total colectomy and ileal pouch anal anastomosis. The patient recovered well and was discharged on postoperative day 8. Endoscopic surveillance after surgery is crucial as ulcerative colitis with polyposis is a risk factor for colorectal cancer. Recognition of polyposis requires clinical, endoscopic and histopathologic correlation, and helps with chemoprophylaxis of colorectal cancer, as the drugs used postoperatively for colorectal cancer, ulcerative colitis and polyposis are different.
International Journal of Clinical and Experimental Medicine | 2014
Jin-Shan Feng; Cancan Guo; Yuzhen Zhu; Liping Pang; Zheng Yang; Ying Zou; Xuebao Zheng
International Journal of Clinical and Experimental Medicine | 2014
Jin-Shan Feng; Zheng Yang; Yuzhen Zhu; Zhou Liu; Cancan Guo; Xuebao Zheng
International Journal of Clinical and Experimental Pathology | 2015
Yuzhen Zhu; Yan-Ling Feng; Hong-Bo Liu; Hua Ye; Cancan Guo; Jinshan Feng; Shi-Xue Dai; Xuebao Zheng
World Chinese Journal of Digestology | 2015
Cancan Guo; Ying Deng; Hua Ye; Yuzhen Zhu; Xuebao Zheng
Chinese Medicine | 2018
Yuzhen Zhu; Yu Zhong; Yu Zhou; Yanyan Liu; Qionglin Huang; Zhe Huang; Yongcun Wang; Hua Ye; Xiaobing Zeng; Xuebao Zheng
International Journal of Clinical and Experimental Pathology | 2015
Hua Ye; Xiaoqing Yang; Kefeng Wu; Li Li; Yingnian Lv; Yi Liu; Xuebao Zheng